MPS IIIA is caused by pathogenic variants in the SGSH gene, which encodes the lysosomal enzyme heparan sulfate sulfamidase (N-sulfoglucosamine sulfohydrolase). This enzyme catalyzes the initial step in the stepwise degradation of heparan sulfate within lysosomes. When SGSH enzymatic activity is absent or severely reduced, heparan sulfate accumulates progressively in lysosomes throughout the body, with neuronal cells being particularly affected. The condition follows an autosomal recessive inheritance pattern, requiring two pathogenic SGSH variants — one inherited from each biological parent — for the disease to manifest. According to GeneReviews, genotype-phenotype correlations have been described for SGSH, indicating that certain variant classes are associated with differences in disease severity or rate of neurological progression, though the specific correlational data are not reproduced in this packet's structured fields. The progressive glycosaminoglycan accumulation resulting from SGSH deficiency disrupts lysosomal function and downstream cellular processes in the central nervous system, producing the characteristic pattern of neurological deterioration with relatively milder somatic involvement.

According to GeneReviews, no formal diagnostic criteria for MPS III have been established. GeneReviews describes that MPS IIIA should be suspected in individuals presenting with language and motor delays at ages 1–3 years, or with behavioral problems including hyperactivity, aggressive behavior, and sleep disturbances between ages 3–10 years. In older individuals, progressive intellectual disability and developmental regression may prompt diagnostic evaluation. GeneReviews describes the diagnostic approach as including biochemical enzyme activity testing — specifically measurement of heparan sulfate sulfamidase (SGSH) enzyme activity in white blood cells or fibroblasts — as a method of confirming enzyme deficiency. Elevated urinary excretion of heparan sulfate is a characteristic laboratory finding associated with the MPS III phenotype. Molecular genetic testing of the SGSH gene confirms MPS IIIA specifically and distinguishes it from the other three MPS III subtypes, which involve distinct genes and enzymes. GeneReviews describes the evaluation following initial diagnosis as encompassing assessment across multiple organ systems, including neurological, developmental, and audiological evaluations, to establish the full extent of disease involvement.

No FDA-approved treatments are certified in this packet for MPS IIIA. GeneReviews states that no treatments are currently clinically available for the primary manifestations of MPS III. According to GeneReviews, hematopoietic stem cell transplantation and umbilical cord blood transplantation are not considered effective therapeutic options for MPS III, given the lack of evidence of meaningful neurologic benefit. GeneReviews further documents that intravenous enzyme replacement therapy is unable to permeate the blood-brain barrier sufficiently to prevent neurologic disease progression, limiting its utility in this condition. Clinical management of MPS IIIA as described by GeneReviews is supportive and symptom-oriented. Seizures are managed with anti-seizure medications as determined by a neurologist. Neurodevelopmental delays are addressed through supportive therapies including speech therapy, physical therapy, and occupational therapy. GeneReviews notes that developmental gains achieved through these supportive approaches may be short-lived given the progressive nature of the disease. Certified approved therapeutic coverage beyond symptom-directed supportive care is not established in this packet.

The prognosis of MPS IIIA is characterized by progressive neurological decline culminating in severe intellectual disability and loss of previously acquired skills. GeneReviews describes universal neurologic deterioration in all affected individuals as a defining feature of MPS III, though clinical variability in the rate and severity of progression is extreme. GeneReviews notes that improvements in symptoms achieved through supportive management are typically not long-lasting, given the underlying progressive course of the disease. Surveillance for deterioration across neurological, developmental, audiological, and orthopedic domains is described by GeneReviews as an appropriate and important component of long-term clinical management. GeneReviews documents that genotype-phenotype correlations for SGSH have been identified, suggesting that variant type may influence disease trajectory, though the specific correlations are not certified in this packet's structured data fields. The combination of progressive intellectual disability, behavioral deterioration, intractable sleep disturbances, recurrent infections, and seizures defines the longitudinal burden experienced by individuals with MPS IIIA.

Four clinical trials focused on MPS IIIA are registered in this packet, reflecting active gene therapy research in this area. NCT02716246 is a Phase 2 gene transfer trial evaluating scAAV9.U1a.hSGSH — an adeno-associated virus vector delivering a functional copy of the SGSH gene — sponsored by Ultragenyx Pharmaceutical Inc. and currently in recruiting status. NCT06181136 is a Phase 1 study of DNL126, an investigational agent in pediatric participants with MPS IIIA, sponsored by Denali Therapeutics Inc. and currently active but not recruiting. NCT06567769 is a Phase 1 study of GC1130A in individuals with Sanfilippo syndrome type A (MPS IIIA), sponsored by GC Biopharma Corp and currently recruiting. NCT04201405 is a Phase 1 gene therapy trial using modified autologous hematopoietic stem cells, sponsored by the University of Manchester and currently active but not recruiting. GeneReviews notes that despite ongoing research into a variety of therapeutic options — including gene therapy approaches — no treatments for the primary manifestations of MPS III are currently clinically available.